CHRNA7 Antikörper (Extracellular Domain, N-Term)

Produktnummer ABIN1842566

Produktdetails anti-CHRNA7 Antikörper

Target: CHRNA7 (Cholinergic Receptor, Nicotinic, alpha 7 (Neuronal) (CHRNA7))

Bindungsspezifität: Extracellular Domain, N-Term

Reaktivität: Human, Ratte, Maus

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser CHRNA7 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB)

Spezifität: Rabbit Anti-CHRNA7 Polyclonal Antibody detects endogenous levels of human, mouse, and rat CHRNA7.
Positive Control: SH-SY5Y lysate, mouse brain lysate and rat brain lysate

Produktmerkmale: Rabbit Anti-CHRNA7 Polyclonal Antibody is developed in rabbit using a KLH-coupled synthetic peptide from N-terminal extracellular domain of human CHRNA7 (Swiss Prot: P36544).

Aufreinigung: Immunoaffinity chromatography

Immunogen: KLH-coupled synthetic peptide from N-terminal extracellular domain of human CHRNA7 P36544

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Working concentrations for specific applications should be determined by the investigator. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product.

Western blot: 0. 5-1 µg/mL

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Rekonstitution: Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final antibody concentration of 0.5 mg/mL.

Konzentration: 0.5 mg/mL

Buffer: lyophilized with PBS, pH 7.4, containing 0.02 % sodium azide

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: WARNING: Reagents contain sodium azide. Sodium azide is very toxic if ingested or inhaled. Avoid contact with skin, eyes, or clothing. Wear eye or face protection when handling. If skin or eye contact occurs, wash with copious amounts of water. If ingested or inhaled, contact a physician immediately. Sodium azide yields toxic hydrazoic acid under acidic conditions. Dilute azide-containing compounds in running water before discarding to avoid accumulation of potentially explosive deposits in lead or copper plumbing.

Handhabung: Avoid repeated freezing and thawing.

Lagerung: -20 °C

Informationen zur Lagerung: The antibody is stable in lyophilized form if stored at -20 °C or below. The reconstituted antibody can be stored for 2-3 weeks at 2-8 °C. For long term storage, aliquot and store at -20 °C or below.

Details zu CHRNA7

Target: CHRNA7 (Cholinergic Receptor, Nicotinic, alpha 7 (Neuronal) (CHRNA7))

Andere Bezeichnung: CHRNA7 (CHRNA7 Produkte)

Synonyme: CHRNA7-2 antikoerper, NACHRA7 antikoerper, dZ70B1.1 antikoerper, Acra7 antikoerper, alpha7 antikoerper, BTX antikoerper, NARAD antikoerper, nAChRa7 antikoerper, CHRNA7 antikoerper, cholinergic receptor nicotinic alpha 7 subunit antikoerper, neuronal acetylcholine receptor subunit alpha-7 antikoerper, cholinergic receptor, nicotinic, alpha 7 (neuronal) antikoerper, cholinergic receptor, nicotinic, alpha polypeptide 7 antikoerper, cholinergic receptor, nicotinic, alpha 7 antikoerper, CHRNA7 antikoerper, LOC100374356 antikoerper, chrna7 antikoerper, Chrna7 antikoerper, LOC100060521 antikoerper

Hintergrund: CHRNA7 (Also known as Nicotinic Acetylcholine Receptor alpha 7) is a major component of brain nicotinic receptors that are blocked by alpha-bungarotoxin. The nicotinic acetylcholine receptors (nAChRs) are members of a superfamily of ligand-gated ion channels that mediate fast signal transmission at synapses. CHRNA7 has a signal peptide, followed by an N-terminal extracellular domain, 3 membrane-spanning regions, an intracellular domain, a fourth transmembrane region, and an extracellular C-terminal tail. The nicotinic acetylcholine receptor alpha-7 subunit is required for acetylcholine inhibition of macrophage TNF release. The nicotinic acetylcholine receptor alpha-7 subunit is essential for inhibiting cytokine synthesis by the cholinergic antiinflammatory pathway. Upregulation of CHRNA7 receptors may be a compensatory response to maintain basocortical cholinergic activity during disease progression or may act with beta-amyloid in disease pathogenesis

UniProt: P36544

Pathways: Synaptic Membrane